Abstract: Objective To analyze the cost-effectiveness of the treatment of type 2 diabetes by 3 different drugs.Methods Through the retrospective analysis of 198 cases with T2DM and drug economics,to analyze the costeffectiveness of the Yamo Li(glimepiride),repaglinide(repaglinide) and Avandia(rosiglitazone).Results No significant difference was observed in the total effective rate among the 3 drugs.The cost-effectiveness ratios in Group A,B and C were 2.99,1.43 and 5.76.The cost-effectiveness ratios increments in Group A,B and C were 42.15,18.32 and 214.74.Conclusion Based on individual differences of the patients,doctor should choose the drug with best treatment,lowest price and highest safety.